PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA

Bibliographic Details
Main Authors:	Rahmathullah Sulaimankutty Nameera, Raghuveer Prabhu
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975412.12587.e6

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS
by: EQ Crusoe, et al.
Published: (2021-10-01)

PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
by: E.Q. Crusoé, et al.
Published: (2020-11-01)

SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
by: EQ Crusoe, et al.
Published: (2021-10-01)

Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients
by: Fang Fang, et al.
Published: (2024-01-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

IMMUNE PROFILING EVALUATION OF NEWLY DIAGNOSE MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS TREATED WITH DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (DARA-CTD): PRELIMINARY RESULTS
by: A.S. Santos, et al.
Published: (2020-11-01)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
by: Qian W, et al.
Published: (2020-01-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
by: Shutan Li, et al.
Published: (2023-03-01)

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
by: Enrique M. Ocio, et al.
Published: (2023-02-01)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
by: M. I. Nuevo López, et al.
Published: (2022-06-01)

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
by: R. M. Rifkin, et al.
Published: (2022-06-01)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
by: Saulius K. Girnius, et al.
Published: (2023-08-01)

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
by: Jingsong He, et al.
Published: (2014-01-01)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
by: X. Jingyu, et al.
Published: (2022-06-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone
by: Xialu Lan, et al.
Published: (2024-03-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
by: Chen R, et al.
Published: (2017-08-01)

PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
by: C. Cerchione, et al.
Published: (2022-06-01)

PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT-INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH
by: Matthew J. Pianko, et al.
Published: (2023-08-01)

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: K. Groen, et al.
Published: (2022-06-01)

P909: RENAL RESPONSE OF POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT
by: Y. Jian, et al.
Published: (2022-06-01)

P909: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: POMACE PHASE II STUDY
by: Fen Saj, et al.
Published: (2023-08-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
by: Ajay K. Nooka, et al.
Published: (2022-04-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Survival and Prognosis Analysis of Bortezomib Based Regimen in Newly Diagnosed Super-aged Multiple Myeloma Patients
by: ZHAO Fengyi, LI Xin, ZHAN Xiaokai, ZHANG Jiajia, SHEN Man, TANG Ran, FAN Sibin, HUANG Zhongxia
Published: (2024-03-01)

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
by: K. Weisel, et al.
Published: (2023-05-01)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
by: Meral Beksac, et al.
Published: (2023-08-01)

PB2125: VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN PATIENTS WITH PRIMARY MULTIPLE MYELOMA (MM): HIGHLIGHTING STRATEGIES THAT ACTUALLY WORK.
by: Olga Novosad, et al.
Published: (2023-08-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
by: Fen Saj, et al.
Published: (2023-03-01)

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
by: Wenjiao Tang, et al.
Published: (2024-01-01)

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
by: H. Elsabah, et al.
Published: (2022-06-01)

PB2128: CLINICAL CONSENSUS ON FIRST-LINE (1L) TREATMENTS FOR TRANSPLANT-INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): DELPHI PANEL OF US HEMATOLOGISTS AND ONCOLOGISTS
by: Rafael Fonseca, et al.
Published: (2023-08-01)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020-12-01)

PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA

Similar Items

Similar Items